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ttp://dx.doi.org/10.1016/j.ajpath.2014.06.008Malignant mesothelioma (MM) is an aggressive tumor with no treatment regimen. Previously we have
demonstrated that cyclic AMP response element binding protein (CREB) is constitutively activated in MM
tumor cells and tissues and plays an important role in MM pathogenesis. To understand the role of CREB in
MM tumor growth, we generated CREB-inhibited MM cell lines and performed in vitro and in vivo exper-
iments. In vitro experiments demonstrated that CREB inhibition results in signiﬁcant attenuation of
proliferation and drug resistance of MM cells. CREB-silenced MM cells were then injected into severe
combined immunodeﬁciency mice, and tumor growth in s.c. and i.p. models of MM was followed. We
observed signiﬁcant inhibition in MM tumor growth in both s.c. and i.p. models and the presence of a
chemotherapeutic drug, doxorubicin, further inhibited MM tumor growth in the i.p. model. Peritoneal
lavage ﬂuids from CREB-inhibited tumor-bearing mice showed a signiﬁcantly reduced total cell number,
differential cell counts, and pro-inﬂammatory cytokines and chemokines (IL-6, IL-8, regulated on acti-
vation normal T cell expressed and secreted, monocyte chemotactic protein-1, and vascular endothelial
growth factor). In vitro studies showed that asbestos-induced inﬂammasome/inﬂammation activation in
mesothelial cells was CREB dependent, further supporting the role of CREB in inﬂammation-induced MM
pathogenesis. In conclusion, our data demonstrate the involvement of CREB in the regulation of MM
pathogenesis by regulation of inﬂammation. (Am J Pathol 2014, 184: 2816e2827; http://dx.doi.org/
10.1016/j.ajpath.2014.06.008)Supported by grants from the NIH (RO1 ES021110 and T32 ES007122),
the Mesothelioma Applied Research Foundation, and the Vermont Genetics
Network (P20GM103449).
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Disclosures: None declared.Malignant mesothelioma (MM) is a very aggressive cancer
originating from the mesothelial lining of the peritoneal,
pleural, or pericardial cavity.1 The incidence of MM con-
tinues to increase worldwide because of the long latency
period of MM development.2 MM is difﬁcult to diagnose at
an early stage and is resistant to conventional and multi-
modal treatments. A combination of cisplatin and peme-
trexed is the current ﬁrst-line chemotherapy regimen for
MM patients.3 Doxorubicin (Dox) was the ﬁrst successful
chemotherapeutic drug tested in MM and is currently
administered in combination with other treatment strate-
gies.4,5 Recent focus for MM treatment includes immuno-
therapy, growth factor receptors, signaling molecular
pathways, angiogenic pathways, and epigenetic modulator
targeting (reviewed by Mossman et al6). Moreover, gene
therapy is seen as a potential therapeutic possibility for MMstigative Pathology.
.(reviewed by Tagawa et al7). As the population of MM
patients is growing worldwide, there is a strong need for the
development of new and effective therapies.
Various signaling molecules have been involved in the
pathogenesis of MM, and targeting them by small-molecule
inhibitors or gene therapy is an ongoing strategy in the
development of chemotherapeutics. An important step in
this direction was our identiﬁcation of extracellular signale
regulated kinases, which play important roles in MM
CREB in Malignant Mesotheliomapathogenesis, and their inhibition by small-molecule in-
hibitors in combination with chemotherapeutic drugs could
have signiﬁcant effects on MM tumor growth.8e10 Cyclic
AMP response element binding protein (CREB) is a tran-
scription factor that mediates signals from calcium, cyto-
kines, and cellular stressors by regulation of gene
expression.11 Although CREB-dependent gene expression
plays signiﬁcant roles in the regulation of various aspects of
the central nervous system, little knowledge exists about the
role of CREB in cancers. Recent limited reports have
demonstrated a signiﬁcant emerging role of CREB in some
cancers. For example, patients with acute lymphoid leukemia
or acute myeloid leukemia show CREB overexpression in
their bone marrow samples, and CREB overexpression is
associated with a poor outcome in AML patients.12 Another
CREB family member, CREB2, was signiﬁcantly elevated in
breast carcinoma compared to corresponding normal breast
tissue and may potentially be involved in the development of
cancer.13 Furthermore, CREB overexpression and activation
has been linked to negative prognosis in nonsmokers with
nonesmall cell lung cancer14 and melanoma metastasis.15
We recently reported that asbestos activates CREB in
mesothelial cells, and MM cells and tumor tissues show
constitutively activated CREB.16 Here, using xenograft
mouse models and genetically CREB-silenced MM cell lines
[small hairpin (sh) CREB], we demonstrate that CREB pro-
motes MM tumor growth in mouse models. Additionally, we
demonstrate that Dox in the presence of CREB silencing is
more effective in MM tumor reduction compared with Dox
alone. Moreover, inﬂammatory proﬁles assessed in perito-
neal lavage ﬂuid (PLF) of i.p. tumor-bearing mice showed
signiﬁcant inhibition in total and differential cell counts, as
well as pro-inﬂammatory cytokines, chemokines, and growth
factor levels in shCREB groups. In vitro data validated
in vivo ﬁndings that showed that asbestos-induced inﬂam-
masome activation in human mesothelial cells, which could
be a source of many pro-inﬂammatory cytokines, is CREB
dependent. Conclusively our data show that CREB controls
MM tumor development and growth by multiple mecha-
nisms, predominantly by regulating inﬂammation.
Materials and Methods
Cell Culture and Treatment with Asbestos and/or
Inhibitors
Human peritoneal mesothelial LP9/TERT-1 (LP9) cells17
were a gift from James Rheinwald (Brigham and
Women’s Hospital, Harvard University, Boston, MA).
Human MM cell lines H2373, H2595, H2461, and HP-1
were contributed by Harvey Pass (New York University,
New York, NY).18 HMESO cells, originally designated
H-MESO-1, were isolated by Reale et al.19 All cells were
cultured as reported previously.9
Cell lines were validated by short tandem repeats DNA
ﬁngerprinting using the Cell ID System (Promega Corp.,The American Journal of Pathology - ajp.amjpathol.orgMadison, WI). The short tandem repeats proﬁles are of
human origin and did not match known DNA ﬁngerprints in
the Cell Line Integrated Molecular Authentication database
(http://bioinformatics.istge.it/clima) but will serve as a
reference for future work.
The physical and chemical characterization of the National
Institute of Environmental Health Sciences reference sample
of crocidolite asbestos has been reported previously.20 Fibers
were added to cells in medium to achieve the desired ﬁnal
concentration of 5 mg/cm2 area dish (represented as 75 in
terms of surface area at some places) as described previ-
ously,21 a concentration causing apoptosis and compensatory
proliferation of surrounding pleural mesothelial cells.22
Protein kinase A (PKA) inhibitor H89 was purchased from
Calbiochem (La Jolla, CA) and was added at an effective
concentration reported previously.16 Control cultures
received medium without inhibitor but with vehicle (0.1%
dimethyl sulfoxide) instead and were treated identically. Dox
was purchased from Sigma-Aldrich Corp. (St. Louis, MO),
and cisplatin was purchased from Alfa Aesar (Ward Hill,
MA). All experiments were performed in duplicate or more.
Creation of shCREB MM Lines
ConﬂuentHMESO orH2373 cells were transfectedwith either
CREB1 or scrambled control Sure Silencing Plasmids (4
shConstructs per gene per cell line were used) from SABio-
sciences (Frederick, MD), using Lipofectamine 2000 (Invi-
trogen, Carlsbad, CA) as previously described.8 After this
procedure, shCREB1 clones exhibiting inhibition of>70% to
80% CREB1 expression were obtained. Inhibition of CREB1
in transfected MM cell lines was determined by quantitative
real-time PCR as well as by Western blot analysis.
Proliferation Assay
Transfected HMESO or H2373 cells (shCon and shCREB1)
were plated at the same density and were allowed to grow
for 72 hours in 12 well plates. Cells were trypsinized and
counted at 0, 24, 48, and 72 hours with a hemocytometer.
MTS Assay
Human MM cells (shCon and shCREB) were treated with
different concentrations of Dox for 24 hours, and cell
viability was measured in cells using the colorimetric MTS
assay CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega Corp., Fitchburg, WI) as per the manu-
facturer’s recommendations.9
Transformation Assay
Anchorage-independent growth of transfected HMESO MM
cells was assessed by a colony-formation assay in soft agar
using the CytoSelect Cell Transformation assay (Cell Bio-
labs, Inc., San Diego, CA) as previously reported.102817
Westbom et alMigration Assay
Migration of MM cells was assessed using 6-well Transwell
polycarbonate ﬁlters (Corning Costar Corp., Corning, NY)
with an 8-mm pore size as described previously.10
S.C. Xenograft Mouse Model
HMESO cells stably transfected with either shCREB1 or
shCon were injected into 4 s.c. sites (5  106 cells per in-
jection site) on the dorsa of 6-week-old Fox Chase severe
combined immunodeﬁciency (SCID) mice (Charles River
Laboratories Inc., Wilmington, MA) (nZ 5 or 6 per group).
At the end of the experiment, all mice were weighed,
euthanized with i.p. injections of sodium pentobarbital, and
necropsied to determine possible gross metastases.10 Tumor
volumes were calculated as described previously.23 All ex-
periments using mice were approved by the Institutional
Animal Care and Use Committee at the University of Ver-
mont College of Medicine (Burlington, VT).
Assessment of Human MM Tumor Development in an
i.p. SCID Mouse Model
CREB-inhibited (shCREB) or control (shCon) HMESO
cells (5  106 cells in 50 mL 0.9% NaCl, pH 7.4) were
injected into the lower left quadrant of the peritoneal cavity
of 6-week-old male Fox Chase SCID mice (nZ 5 or 6 mice
per group). Two weeks after cell injection, two groups
(shCon-Dox and shCREB1-Dox) started receiving 0.5 mg/
kg Dox i.p., t.i.w. for 2 weeks. The other two groups
(shCon-saline and shCREB-saline) received equal volumes
of saline for the same period of time. Four weeks after MM
cell injections, mice were euthanized as described above.
PLF was collected, and animals were closely examined for
the presence of tumors. Weights and volumes of tumors
were determined as reported previously.24 Brieﬂy, tumor
volumes were measured using calipers and calculated using
the following formula:
ðp  long axis  short axis  short axisÞ=6 ð1Þ
and were not based on tumor weights. As i.p. MM tumors
developed attached to mesentery, individual numbers could
not be counted.
Generation of CREB-Overexpressing MM Lines and
Injection into Mice
CREB-overexpressing HMESO MM lines were generated
by the transfection of plasmid-containing CREB1 human
cDNA clone (transfection ready; OriGene Technologies,
Inc., Rockville, MD) or empty vector (PCMV6NEO; Ori-
Gene Technologies, Inc.) into cells and then after the se-
lection process and limited dilution as described above.
These cells were injected i.p. into mice as discussed above,
and tumor growth was followed for 4 weeks.2818Determination of Inﬂammatory Cell Proﬁles in PLF in
the I.P. SCID Mouse Model
After the euthanization of the mice, PLF was collected as
described previously.24 Cells were stained with white blood
cell stain and counted. For total cell counts, we stained PLF
samples with white blood cell stain, suggesting that total
cell counts included all nucleated cells, including meso-
thelial/mesothelioma cells. During differential cell count-
ing, we saw clumps of mesothelioma cells that were not
included in the blood cell counts. After proper processing,
PLF was used for cytokine, chemokine, and growth factor
analysis and for differential cell count assessment.24 PLF
was selected over serum for inﬂammatory marker assess-
ment, as our previous experiments (unpublished data)
showed that inﬂammatory changes are detectable in PLF,
but are not signiﬁcantly reﬂected in serum, at week 4 of
experimentation.
Cytokine, Chemokine, and Growth Factor Assessment
in PLF
To quantify cytokine and chemokine levels in PLF from
mice, a multiplex suspension protein array was performed
using a Human Cytokine 27-plex panel (Bio-Rad Labora-
tories, Inc., Hercules, CA) as described previously.25 Con-
centrations of each cytokine and chemokine were determined
using Bio-Plex Manager version 3.0 software. Data were
expressed as pg cytokine/mL medium.
TUNEL Staining in Tumors
Parafﬁn sections of shCon and shCREB tumors collected
from the in vivo model were dehydrated and processed for
antigen retrieval (Dako, Carpinteria, CA). Slides were then
transferase dUTP nick end labeling (TUNEL) stained using
Roche’s (Indianapolis, IN) In Situ Cell Death Detection Kit,
POD, using the recommended protocol for processing
difﬁcult tissue. Images of TUNEL-stained tumor tissue were
taken using a 40 objective with an Olympus BX50 upright
light microscope (Olympus America Inc., Lake Success,
NY) and an attached QImaging Retiga 2000R Digital CCD
Camera (Advanced Imaging Concepts, Inc., Princeton, NJ).
Western Blot Analysis
Western blot analysis was performed as described previ-
ously,26 using antibodies speciﬁc to total and phosphory-
lated CREB [rabbit polyclonal anti-phosphoCREB, 1:500;
rabbit polyclonal anti-CREB, 1:1000 (Cell Signaling
Technology, Inc., Beverly, MA); and total b-actin 1:2000
(Abcam plc, Cambridge, UK)]. QuantityOne was used to
quantify band density, and phosphorylated protein levels
were normalized to respective total protein levels (ie,
phosphoCREB/CREB). Blots are representative of at least
two different experiments.ajp.amjpathol.org - The American Journal of Pathology
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Supernatants (Medium) of Mesothelial and MM Cells
Medium was collected (500 mL) and concentrated using
Amcion ultracentrifugal ﬁlters with a 10K membrane (EMD
Millipore, Billerica, MA) as described previously.21 Western
blots were performed as previously described26 on both cell
lysates and concentrated medium. A rabbit polyclonal high-
mobility group box 1 protein (HMGB1) antibody (Abcam
plc) was used at a dilution of 1:5000. Rabbit polyclonal an-
tibodies for caspase-1 p20 (Cell Signaling Technology, Inc.)
were used at 1:500 dilutions. Western blot analysis per-
formed in medium had no normalization control (eg, b-actin),
and quantitation represents the band density of each sample.
Enzyme-Linked Immunosorbent Assay for IL-1b
and IL-18
The Quantikine Human IL-1b/IL-1f2 Immunoassay (R&D
Systems, Inc., Minneapolis, MN; measures predominantly
mature IL-1b) was used on concentrated cell medium, pre-
pared as described previously,21 and the assay was performed
according to the manufacturer’s instructions. IL-18 release
was measured using the Human IL-18 enzyme-linked
immunosorbent assay kit (MBL International Corp.,
Woburn, MA; measures predominantly active IL-18, 0.7%
pro IL-18).21 Values were expressed as pg/mL of IL-1b or
IL-18 from the original supernatant (nonconcentrated).
Caspase-1 Activity Assay
Caspase-1 activity was measured using the Caspase-1
Colorimetric Assay Kit (R&D Systems, Inc.) as previously
reported.21 Protein concentrations were determined by the
Bio-Rad protein assay27 using the remaining lysate.
Quantitative Real-Time PCR
Total RNA was prepared using an RNeasy Plus Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer’s
protocol as described previously.26 Total RNA (1 mg) was
reverse-transcribed with random primers using the Avian
Myeloblastosis Virus Reverse Transcriptase kit (Promega
Corp., Madison, WI) according to the recommendations of
the manufacturer. Gene expression was quantiﬁed by Taq-
Man quantitative real-time PCR using the Prism 7700
Sequence Detector (PerkinElmer/Applied Biosystems Inc.,
Foster City, CA) as described previously.10 Duplicate/trip-
licate assays were performed with RNA samples isolated
from at least two independent experiments.
Affymetrix Gene Proﬁling
Microarrays were performed on samples from three inde-
pendent experiments as described previously.28 Each of the
samples was analyzed on a separate array, that is, n Z 3The American Journal of Pathology - ajp.amjpathol.orgarrays per MM cell line (three independent biological repli-
cates) (shCon and shCREB). A Human Genome U133A 2.0
Array (Affymetrix, Inc., Santa Clara, CA) was scanned twice
(HP GeneArray Scanner; Hewlett-Packard, Palo Alto, CA),
the images overlaid, and the average intensities of each probe
cell compiled. Microarray data were analyzed using Gene-
Sifter software (VizX Labs, Seattle, WA). This program used
a t-test for pairwise comparison and a Benjamini-Hochberg
test for false discovery rate (5%) to adjust for multiple
comparisons. A twofold cutoff limit was used for signiﬁcance
(Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/
geo, accession no. GSE51447).
Statistical Analysis
In all in vitro assays, at least two independent samples were
examined at each time point per group in duplicate or trip-
licate experiments. Data were evaluated by either analysis of
variance using the Student-Neuman-Keuls procedure for
adjustment of multiple pairwise comparisons between treat-
ment groups, the nonparametric Kruskal-Wallis and U–tests,
or a two-tailed t-test. P values  0.05 were considered sta-
tistically signiﬁcant. The difference in tumor growth rates in
the s.c. MM model was assessed using a hierarchical
regression model to take into account the correlation between
repeated measurements on the same tumor and multiple tu-
mors in the same animal. In this analysis, the regression co-
efﬁcient describing tumor growth is modeled as a function of
treatment group as well as random variation due to differ-
ences between animals and tumors on the same animal.
Results
CREB Silencing in MM Cell Lines Causes Reduced
Tumorigenic Properties
We generated two stably inhibited CREB MM lines
(HMESO and H2373) and assessed them for various in vitro
tumorigenic properties (Figure 1). Both MM lines showed
signiﬁcant inhibition in CREB levels as measured at the RNA
and protein levels (Figure 1A). CREB silencing in both MM
cell lines demonstrated inhibition in proliferation (Figure 1B)
and increased Dox sensitivity (Figure 1C). In addition, col-
ony formation and migration were inhibited by CREB
attenuation in HMESO MM cells (Figure 1, D and E).
CREB Inhibition Causes Attenuated Tumor Growth in
Xenograft Mouse Models
After in vitro testing, stably inhibited CREB MM cells
(HMESO) were injected into mice either s.c. or i.p. as
described earlier. Figure 2A shows the remarkably different
tumor sizes from the shCon and shCREB groups in the s.c.
model. Tumor in this model grew for 45 days, and the
median tumor volumes were 0.62172 and 0.00052 in the
shCon and shCREB groups, respectively. Signiﬁcantly2819
Figure 1 Creation and characterization of shCREB malignant mesothelioma (MM) lines. A: shCREB HMESO and H2373 MM lines show decreased levels of CREB
after shCREB transfection. BeE: CREB inhibition represses proliferation of MM lines (B), makes MM lines more sensitive to the chemotherapeutic drug Dox (C),
causes attenuation of colony formation by MM cells (D), and reduces MM cell migration (E). Data are expressed as means SEM (AeC, E). nZ 2 to 6. *P< 0.05
versus untreated (0) of same sh group; yP < 0.05 versus shCon of same treatment group. OD, optical density, in nm.
Westbom et algreater inhibition in MM tumor growth rate was observed in
the shCREB group compared with the shCon group in the
same model, as assessed by a biostatistician as described in
Statistical Analysis section (Figure 2B). Tumor volumes in
the shCREB group were very small (0, 0.00028, 0.001,
0.00094, 0.00087, 0.00098, 0.00174, and 0.00560) but not
zero as appears from the scale. The tumor volumes in the
two groups were also signiﬁcantly different at various time
points. TUNEL staining to assess cell death in tumors
showed increased staining in CREB-inhibited tumors
(Figure 2C); representative sections from same animals
stained for hematoxylin and eosin and phosphoCREB are
also included in Figure 2C. The differences in cell viability
may have been the result of pCREB, hematoxylin and eosin,
and TUNEL staining performed on different sections rep-
resenting different areas of the same tumor.
I.p. injection of CREB-inhibited MM cells also resulted
in signiﬁcantly reduced tumor weights and volumes
compared with those in control tumors (Figure 2, D and E).
Treatment with Dox resulted in further reductions in tumor
weights and volumes (Figure 2, D and E), suggesting that
combined CREB inhibition and chemotherapy is better than
either of them alone. The volumes of PLF were not
signiﬁcantly different between the two groups.
To show that overexpression of CREB has an effect on
tumor growth opposite that of CREB silencing, we gener-
ated CREB-overexpressing MM cell lines and injected them
i.p. into SCID mice. As expected, CREB overexpression
had no inhibitory effect on MM tumor weights and volumes
(Figure 2, F and G).
The use of two different in vivo models (i.p. and s.c.;
Figure 2) to show that CREB is involved in MM tumori-
genesis reinforced our ﬁndings.2820Reduced Inﬂammation by CREB Silencing in the I.P.
MM Tumor Model
PLF from i.p. human MM tumorebearing SCID mice were
assessed for inﬂammatory responses. Total cell counts in PLF
from control and Dox-treated mice were not signiﬁcantly
different [total cell counts reﬂect only immune cells, macro-
phages, neutrophils, and eosinophils (lymphocyte counts were
not included as SCID mice do not have lymphocytes); meso-
thelial/mesothelioma cells were not included in the total cell
counts]. However, CREB inhibition alone and in combination
with Dox showed a decrease in total cell number (Figure 3A).
Differential cell counts also showed the same pattern
(Figure 3B).We studied a panel of human cytokines in PLF by
BioPlex analysis. Use of the human panel ensured that the
cytokines measured were derived from MM tumors and not
from the host (mice). CREB silencing attenuated many pro-
inﬂammatory cytokines, chemokines, and growth factors
[e.g., IL-6, IL-8, IP-10, monocyte chemotactic protein 1,
macrophage inﬂammatory protein 1b, chemokine (C-X-C
motif) ligand 5/regulated on activation normal T cell expressed
and secreted, and vascular endothelial growth factor]
compared with controls (Figure 3C). In contrast, Dox treat-
ment signiﬁcantly increased the levels of IL-6, IL-8, IP-10,
macrophage inﬂammatory protein 1b, and regulated on acti-
vation normal T cell expressed and secreted (Figure 3C). The
combined effect of Dox and CREB inhibition in many cases
was signiﬁcantly better than that with either of them alone
(Figure 3C). Very low levels of IL-1b were detected in the
PLF, which is consistent with our previous ﬁndings,24 and
there were no signiﬁcant differences across groups. In addi-
tion, IL-18 (another inﬂammasome-related cytokine) could not
be measured as it was not a part of the BioPlex panel.ajp.amjpathol.org - The American Journal of Pathology
Figure 2 CREB inhibition attenuates in vivo malignant mesothelioma (MM) tumor growth in xenograft mouse models. A: Excised control or shCREB
tumors. B: Tumor growth rate in a s.c. model. C: TUNEL staining of tumors from the s.c. model, phosphoCREB, and hematoxylin and eosin (HþE)
stained sections from same animals. D and E: Combined effects of CREB inhibition and 0.5 mg/kg chemotherapeutic drug Dox on peritoneal MM tumor
weights (D) and volumes (E). F and G: CREB overexpression has no inhibitory effect on MM tumor growth in i.p. model. Data are expressed as means 
SEM (B, DeG). n Z 5 to 6. *P < 0.05 versus untreated (0) of same sh group; yP < 0.05 versus shCon of same treatment group. Scale bars Z 1 cm (A)
and 50 mm (C).
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Inﬂammasome Activation in Human Mesothelial Cells
Inﬂammation plays determining roles in asbestos-induced
lung diseases, including MMs. Recent reports show that
NLR family, pyrin domain containing 3 (NLRP3) inﬂam-
masome activation plays a contributory role toward
asbestos-induced inﬂammation in macrophages29 as well as
in mesothelial cells.21 To assess the role of CREB in
asbestos-induced activation of NLRP3, and therefore in
asbestos-induced inﬂammation, in mesothelial cells, we
used a PKA inhibitor, H89, to block CREB activation by
asbestos. This inhibitor was chosen based on our previous
ﬁndings that asbestos-induced CREB activation in meso-
thelial cells is PKA mediated.16 The inhibition of CREB
activation by H89 caused signiﬁcant inhibition in asbestos-
induced NLRP3 priming and activation (Figure 4A). As
NLRP3 activation is measured by caspase-1 activation, here
we measured caspase-1 activation by two techniques,
enzyme activity assay and caspase-1 p20 release in the
medium (Figure 4A), and using both techniques we showed
that CREB inhibition attenuated asbestos-induced NLRP3
activation. Asbestos-induced secretion of the
pro-inﬂammatory marker HMGB1 in medium was also
signiﬁcantly attenuated by CREB inhibition (Figure 4A).
Furthermore, the secretion of IL-1b and IL-18, two key pro-
inﬂammatory cytokines released as a result of inﬂamma-
some activation, was also signiﬁcantly attenuated by CREB
inhibition (Figure 4A). To further conﬁrm the role of CREB
in inﬂammasome priming and activation, we used theThe American Journal of Pathology - ajp.amjpathol.orgCREB-silenced human MM cell line (shCREB) described
above. In CREB-silenced MM cells (HMESO), signiﬁcantly
decreased IL-1b steady-state mRNA levels were observed
(Figure 4B). PYCARD, another subunit required to form a
complex with NLRP3 for inﬂammasome activation, was
also signiﬁcantly inhibited in CREB-silenced MM cells
(Figure 4B). No signiﬁcant effect of CREB silencing on
NLRP3 steady-state mRNA levels was observed (data not
shown). In the assessment of caspase-1 activation, measured
by p20 release into the medium, untreated CREB-silenced
MM cells had slightly (HMESO) (Figure 4B) increased
levels of caspase-1 compared with shCon. Treatment with
the chemotherapeutic drug Dox (5 mmol/L) or cisplatin (100
mmol/L) did not signiﬁcantly alter caspase-1 activation
(Figure 4B). HMGB1, another pro-inﬂammatory molecule
that may be secreted in response to inﬂammasome activa-
tion, also showed no signiﬁcant response in MM cells
(Figure 4B) after CREB inhibition. However, HMGB1
levels were signiﬁcantly lower in the drug-treated shCREB
group compared with those in the respective control groups
(Figure 4B). IL-1b secretion was not signiﬁcantly affected
by CREB silencing or drug exposure in HMESO cells (data
not shown). The data presented here suggest that CREB can
regulate asbestos-induced inﬂammation in mesothelial cells
by modulating inﬂammasomes, which may thereby interfere
with the development of MM. In MM (HMESO) cells,
CREB silencing caused decreased levels of IL-1b and
PYCARD mRNA as well as increased levels of caspase-1
release, resulting in reduced inﬂammation and increased
cell death, which may inhibit the progression of MM.2821
Figure 3 Inhibition of CREB attenuates inﬂammation in human tumorebearing SCID mice. A: Total cell counts in peritoneal lavage ﬂuid (PLF) of tumor-
bearing mice. B: Differential cell counts in PLF of tumor-bearing mice. C: Human proinﬂammatory cytokine, chemokine, and growth factor levels, as measured
by BioPlex, in PLF of tumor-bearing mice. Data are expressed as means  SEM. nZ 5 to 6. *P < 0.05 versus untreated (0) of same sh group; yP < 0.05 versus
shCon of same treatment group.
Westbom et alDifferent Kinases and Phosphatases Regulate CREB
Activation in MM Cells
We have previously shown that MM cells show constitu-
tively activated CREB16; however, upstream pathways
leading to CREB activation in MM cells remain unknown.
To investigate upstream pathways that may regulate the
CREB pathway in MM cells, we selected various inhibitors
that have been demonstrated to regulate CREB phosphor-
ylation in different cell types. We used ﬁve different MM
cell lines16 and inhibitors of epidermal growth factor2822receptor (AG1478), extracellular signaleregulated kinase 1/
2 (U1026), PKA (H89), phosphatidylinositide 3-kinase
(LY), and c-Met (c-Met kinase inhibitor II). No single in-
hibitor was effective in all MM cell lines (Figure 5). We
assessed the levels of phosphatase and tensin homolog in
various MM cell lines with constitutive CREB activation16
because phosphatases can also regulate the activation of
CREB, and a recent report suggested CREB as a target of
phosphatase and tensin homolog phosphatase.30 The
HMESO cell line was the only MM cell line that showed
decreased phosphatase and tensin homolog levels comparedajp.amjpathol.org - The American Journal of Pathology
Figure 4 CREB regulates asbestos-induced inﬂammasomes in human mesothelial cells. A: Asbestos-induced NLRP3 priming is inhibited by attenuation of
CREB activation by 10 mmol/L H89. Asbestos-induced caspase-1 activation is attenuated by CREB inhibition. Asbestos-induced IL-1b, IL-18, and HMGB1 levels
in medium are also inhibited by CREB inhibition. B: CREB inhibits HMESO cells (shCREB) showing decreased IL-1b and apoptosis-associated speck-like protein
containing a CARD (PYCARD) mRNA levels and secreted caspase-1 p20 and HMGB1 levels compared with control HMESO cells (shCon). Data are expressed as
means  SEM. nZ 2 to 3. *P < 0.05 versus untreated (0) group; yP < 0.05 versus Asb (75) group; zP < 0.05 versus untreated (0) of same sh group; xP < 0.05
versus shCon of same treatment group.
CREB in Malignant Mesotheliomawith those in mesothelial cells (LP9) (Figure 5F). From this
experiment, we conclude that it is difﬁcult to inhibit the
activation of CREB in MM cells by a single small-molecule
inhibitor. A superior approach is to inhibit CREB levels by
genetic manipulation (shRNA) or to inhibit the interaction
of active CREB to its partner CREB-binding protein
(KG501).
CREB Silencing Alters Various Tumorigenesis-Related
Genes in MM Cells
As CREB is a transcription factor and plays important roles in
various gene regulations, we screened MM cell lines for the
genes regulated by CREB. Microarray analyses were per-
formed on MM cell lines (HMESO and H2373) stably
inhibited for CREB and respective controls. Selected
tumorigenesis-related genes signiﬁcantly altered by CREB
inhibition in HMESO MM cells are presented in Table 1.
Proliferation- and growth-related genes p21(cyclin-dependentThe American Journal of Pathology - ajp.amjpathol.orgkinase inhibitor 1A)-activated kinase 7 (PAK7), Met proto-
oncogene [c-MET/hepatocyte growth factor receptor
(HGFR)], v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene (oncogenic KIT), and Polo-like kinase 2 (PLK )
were signiﬁcantly inhibited by CREB silencing. Several genes
directly or indirectly involved in the process of angiogenesis
[tyrosine kinase with immunoglobulin-like and endothelial
growth factorelike domains1 (TIE), melanoma cell-adhesion
molecule (MCAM/CD146), pro-inﬂammatory chemokine
(c-c) ligand 5 (CCL5/regulated on activation normal T cell
expressed and secreted)] that are overexpressed in many
cancers and play important roles in angiogenesis, proliferation,
and invasion of tumor cells were all signiﬁcantly attenuated by
CREB inhibition. Furthermore, CREB silencing also down-
regulated some adhesion and migration-related genes, such
as CD24 and matrix metalloprotease 2 (MMP2), that control
the metastasis of tumors. We also validated three different
genes (Table 1) by quantitative real-time PCR from RNA
obtained from a different experiment. Taken together, our2823
Figure 5 CREB regulation in malignant mesothelioma (MM) cells is multifaceted. AeE: Different human MM cell lines exposed to various small-molecule
inhibitors show varied responses. F: Phosphatase and tensin homolog inhibition is observed in one in ﬁve MM lines tested.
Westbom et alﬁndings suggest that CREB may regulate MM tumorigenesis
by regulating many relevant genes.Discussion
MM is a deadly cancer without any effective treatment and
it is therefore important to investigate any potential lead
observed in MM pathogenesis or therapeutic strategies. Our
previous studies have demonstrated that CREB is constitu-
tively activated in MM cells and in tumor tissues and that its
inhibition by siRNA can result in increased apoptosis and
decreased migration.16 These ﬁndings encouraged us to look
further into the role of CREB in MM tumor growth using
in vivo models. Because of the highly heterogeneous nature
of MMs, we could not identify a common kinase or phos-
phatase pathway for CREB activation (Figure 5) in the
different MM cell lines. As a solution to this problem, we
generated shCREB in two MM cell lines (HMESO and
H2373) to generate CREB1-silenced MM cell lines and then
used these lines to study the effect of CREB on MM
tumorigenesis.
In vitro characterization of stable lines showed a signiﬁ-
cant effect of CREB inhibition on the proliferation, drug
resistance, and migration of human MM cells. Many sig-
niﬁcant gene changes observed by microarray analysis
(Table 1) performed on these MM cell lines may be2824correlated with observed in vitro anti-tumorigenic effects.
For example, decreases in the expression of PAK7, a pro-
liferation and survival signalerelated gene; c-MET, a re-
ceptor for hepatocyte growth factor that stimulates
chemotaxis and growth of MM cells30; and oncogenic v-kit,
a proliferation-related gene often mutated in gastrointestinal
stromal tumors,31 by CREB inhibition may in part be
involved in the decreased proliferation and transformation
observed in shCREB MM cell lines. In addition, signiﬁcant
attenuation in migration and motility related genes such as
MMP2 and CD2432 by CREB inhibition may play a role in
reduced migration in shCREB MM cells.
The injection of stable MM cells inhibited for CREB into
SCID mice signiﬁcantly attenuated human MM tumor growth
in two in vivo (i.p. and s.c.) xenograft models (Figure 2). The
use of two different in vivo models strengthens our ﬁndings.
Reduced tumor growth in CREB-inhibited lines could be
attributed in part to increased cell death in shCREB s.c. tu-
mors, as shown by TUNEL staining (Figure 2). Inhibition of
proliferation- and growth-related genes as a consequence of
CREB silencing, as mentioned above, may also be involved
in reduced tumor growth in both models.
The assessment of inﬂammation in the PLF of i.p. tumor-
bearing mice revealed a signiﬁcant effect of CREB inhibi-
tion on total and differential cell counts as well as on
pro-inﬂammatory human cytokines, chemokines, and
growth factors (Figure 3). The decreased inﬁltration ofajp.amjpathol.org - The American Journal of Pathology







p21(CDKN1A)-activated kinase 7/PAK7 23.16 Proliferation/cell survival Validated
Tyrosine kinase with immunoglobulin-like and EGF-like domains, Tie-2/TEK 11.92 Angiogenesis
Melanoma cell adhesion molecule, CD146, MUC18/MCAM 9.65 Cell adhesion/angiogenesis
CD24 molecule/CD24 6.49 Cell adhesion/cell motility
RANTES/CCL5 3.2 Inflammation, angiogenesis
Met proto-oncogene, cMET, HGFR/MET 3.02 Proliferation/growth
Polo-like kinase 2/PLK1 2.81 Oncogenesis
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene, c-Kit/KIT 2.75 Oncogenesis
Matrix metalloprotease 2/MMP2 2.65 Migration/invasion Validated
Interleukin-6/IL6 2.42 Inflammation Validated
CDKN1A, cyclin-dependent kinase inhibitor 1A; EGF, endothelial growth factor; HGFR, hepatocyte growth factor receptor; RANTES, regulated on activation
normal T cell expressed and secreted.
CREB in Malignant Mesotheliomamacrophages, neutrophils, and eosinophils in the PLF of
shCREB tumor-bearing mice could be due to the reduced
levels of monocyte chemotactic protein-1 and macrophage
inﬂammatory protein 1b observed in the same group.
Another chemokine, regulated on activation normal T cell
expressed and secreted/CCL5, attracts eosinophils and is
known to be secreted by many cell types, including meso-
thelial cells,33 and promotes angiogenesis. The pro-angiogenic
cytokines CCL5, chemokine (C-X-C motif) ligand 8 (IL-8),
and vascular endothelial growth factor, which play important
roles in MM tumor growth,34,35 were signiﬁcantly attenuated
by CREB silencing. In support of our ﬁndings, the regulation
of chemokine (C-X-C motif) ligand 8 by CREB has been re-
ported previously36 in nonesmall cell lung cancer. Vascular
endothelial growth factor regulation by CREB either directly
or indirectly has also been documented in cancer and non-
cancer cells.36,37 Moreover, CREB has previously been shown
to regulate inﬂammatory responses either by regulating direct
gene transcription of pro-inﬂammatory genes (IL2, IL6, IL10,
and TNF-a) or by inhibiting NF-kB activation by blocking the
binding of CREB-binding protein to the NF-kB complexes.38
Another pro-inﬂammatory cytokine, IL-6, which is regulated
by CREB38 and is heavily involved in the carcinogenesis
process of many cancers including MM,39 was signiﬁcantly
down-regulated in the PLF of shCREB mice. Our ﬁndings
here demonstrate that CREB-induced inﬂammation may play
a signiﬁcant role in MM tumor growth, and CREB inhibition
may be the crucial ﬁrst step in MM therapy.
Dox was the ﬁrst successful chemotherapeutic drug tested
in MM and is currently administered in combination with
other strategies.4,5 We selected Dox for our studies to use in
combination with CREB inhibition. Here, the observed
ﬁndings of Dox-induced increases in levels of various cyto-
kines and chemokines could be due to the fact that Dox can
activate CREB16 as well extracellular signaleregulated ki-
nases34,36 in MM cells. In addition to Dox, another chemo-
therapeutic drug, tamoxifen, has also been reported to
activate CREB.40 Our data here suggest that chemothera-
peutic drugs may work better in combination with CREBThe American Journal of Pathology - ajp.amjpathol.orginhibitor than alone. Our in vitro (Figure 1) as well as in vivo
(Figure 2) data also show that CREB inhibition can sensitize
MM cells and tumors to Dox-induced cell death (or tumor
reduction). In support of our ﬁndings, recent studies have
reported that increased CREB expression and/or phosphor-
ylation can result in anthracyclin/Dox drug resistance in he-
patocellular carcinoma and myeloid leukemia,41e43 again
emphasizing that CREB inhibitor in combination with
chemotherapeutic drugs may work better than drugs alone.
To validate the role of CREB in asbestos-induced
inﬂammation, we performed in vitro studies using human
mesothelial cells (origin cell for MM). Our work has pre-
viously demonstrated that asbestos can prime and activate
NLRP3 inﬂammasome in mesothelial cells involving an
autocrine loop.21 Inﬂammasome activation is one of the
several ways that asbestos can activate the process of
inﬂammation in mesothelial cells.
To understand the role of CREB in asbestos-induced
inﬂammasome priming and activation, we used PKA in-
hibitor (H89), a kinase that has been shown to phosphory-
late CREB in mesothelial cells in response to asbestos
exposure.16 Our results demonstrate that asbestos-induced
NLRP3 priming and activation in part are regulated by
CREB (Figure 4A).
Along with the pro-inﬂammatory cytokines IL-1b and
IL-18, a pro-inﬂammatory marker, HMGB1, was released as a
result of NLRP3 activation by asbestos and was also inhibited
by CREB attenuation. HMGB1, depending on its location, can
perform double functions. It can act as an oncogenic molecule
or as a tumor suppressor.44 In support of our ﬁndings, the
involvement of CREB-binding protein in lipopolysaccharide
(LPS)-induced relocation and release of HMGB1 in murine
macrophages has recently been reported.45 CREB inhibition
signiﬁcantly attenuated HMGB1 release but had no effect on
intracellular levels of HMGB1 (data not shown).
The role of CREB in IL-1b-induced C-X-C chemokine
gene overexpression in nonesmall cell lung cancer and in
IL-18 transcriptional regulation in the development of T
helper type 1 has been previously documented.36,46 As2825
Westbom et alpreviously reported,16 human MM cells show constitutive
activation of CREB, and in the present study, inhibition of
CREB with shRNA caused signiﬁcant inhibition in steady-
state mRNA levels of IL-1b. Our data substantiates the role
of CREB in IL-1beinduced C-X-C chemokine gene over-
expression in nonesmall cell lung cancer, as reported
earlier.38 Low levels of secreted IL-1b were detected in
medium of shCon cells, and shCREB had no further effect
on IL-1b levels (data not shown). Similarly, in the PLF from
in vivo study, IL-1b levels were very low, and no signiﬁcant
differences across different groups were observed (data not
shown). This ﬁnding is supported by our published and
unpublished studies in which HMESO cells had low NLRP3
steady-state mRNA levels (required to process IL-1b) (un-
published data) and in which HMESO tumors secreted very
low levels of IL-1b in a xenograft model.24 The in vitro
studies support the role of CREB in asbestos-induced
inﬂammation by inﬂammasome activation in mesothelial
cells and a possible role in the initiation of MM. In addition,
signiﬁcantly reduced IL-1b steady-state mRNA levels by
CREB silencing in HMESO MM cells may in part be
involved in the observed reduced inﬂammation and tumor
growth. The in vitro pro-inﬂammatory effect of CREB is
also evident from reduced asbestos- or chemotherapeutic
drugeinduced HMGB1 levels in CREB-inhibited cells.
Conclusion
Our ﬁndings suggest that CREB regulates MM tumor
growth by multiple-gene regulation. More importantly,
CREB-regulated inﬂammation may play a determining role
in the process of MM development and progression. Our
study also suggests that chemotherapeutic drugs alone can
enhance the process of drug resistance or inﬂammation due
to CREB activation. Based on these ﬁndings, it may be
advisable to attenuate CREB function along with chemo-
therapeutic drugs for MM therapy. As a future direction of
our research, we plan to conduct preclinical studies using
CREB-interaction inhibitor (KG-501) in combination with
cisplatin or pemetrexed to slow MM tumor growth.
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